Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Accounts Payables data on file, last reported at $150.3 million in Q4 2025.

• In Q4 2025, Accounts Payables rose 64.3% year-over-year to $150.3 million; the TTM figure through Dec 2025 stood at $150.3 million (up 64.3% YoY), while the FY2025 annual figure was $150.3 million, up 73.23% from the prior year.
• Accounts Payables climbed to $150.3 million in Q4 2025, from $91.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $150.3 million in Q4 2025 and bottomed at $21.4 million in Q4 2023.
• A 3-year average of $87.7 million and a median of $91.5 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables soared 328.07% — and 2025, when it jumped 64.3%.
• Year by year, Accounts Payables stood at $21.4 million in 2023, then jumped by 328.07% to $91.5 million in 2024, then jumped by 64.3% to $150.3 million in 2025.
• The last three Accounts Payables figures came in at $150.3 million (Q4 2025), $91.5 million (Q4 2024), and $21.4 million (Q4 2023), per Business Quant data.

Peer Comparison